Response Biomedical finally triumphs with heart diagnostic
This article was originally published in Clinica
Executive Summary
Response Biomedical appears to have seen a turnaround in its fortune, after the US FDA finally gave it the green light to market its point-of-care RAMP myoglobin test for the rapid diagnosis of heart attacks.